across oncology. worldwide · partners, novartis, peptomyc, pfizer, pharmacyclics, proteodesign sl,...
Post on 12-Jun-2020
5 Views
Preview:
TRANSCRIPT
DECLARATION OF INTEREST
Josep Tabernero reports personal financial interest in form of scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Inc., Genmab A/S, Halozyme, Imugene Limited, Inflection Biosciences Limited, Ipsen, Kura Oncology, Lilly, MSD, Menarini, Merck Serono, Merrimack, Merus, Molecular Partners, Novartis, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign SL, Rafael Pharmaceuticals, F. Hoffmann-La Roche Ltd, Sanofi, SeaGen, Seattle Genetics, Servier, Symphogen, Taiho, VCN Biosciences, Biocartis, Foundation Medicine, HalioDX SAS and Roche Diagnostics.
Josep Tabernero declares institutional financial interest in form of financial support for clinical trials or contracted research for Agendia BV, Amgen SA, Debiopharm International SA, Janssen-Cilag SA, Mologen AG, Novartis Farmacéutica SA, Pharma Mar, Roche Farma SA, LaboratoriosServier SL and Symphogen A/S.
ESMO IN A NUTSHELLAcross oncology. Worldwide
ESMO is the leading European professional organisation for medical oncology, working across Europe and around the world to erase boundaries in cancer care and to provide medical oncology education within an integrated approach to cancer
care
ESMO MEMBERSA global community
>20,000 members
150 countries
Reciprocity agreements with 41 national oncology societies
ESMO MEMBERS IN LATIN AMERICA1,418 members from 29 countries
Figures as at 31 December 2018
+21% increase from 2017+150% increase over last 5 years+254% increase over last 10 years
Latin AmericaBrazil 436 Honduras 7Mexico 332 Jamaica 5Argentina 167 Venezuela 5Peru 119 Nicaragua 4Colombia 93 Bahamas 3Chile 51 Curacao 3Cuba 24 Trinidad Tobago 3Costa Rica 21 Guadeloupe 2Dominican Rep. 19 Guyana 2Uruguay 19 Barbados 1Bolivia 17 Belize 1Paraguay 15 Haiti 1El Salvador 13 Martinique 1Panama 13 Suriname 1Guatemala 10 TOT 1,418
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018Latin America 400 513 439 466 341 568 736 877 1174 1418
0
200
400
600
800
1000
1200
1400
1600
# Act
ive M
embe
rs
Latin America - MBS Trend 2009-2018
ONCOLOGYPROAccess to essential and updated resources anywhere, anytime
Daily news E-learning modules Slide sets Full access articles ESMO books Webcasts
ESMO CLINICAL PRACTICE GUIDELINESProviding oncology professionals with recommendations for the best standards of cancer care
Latest recommendations for diagnosis, disease
staging, risk assessment, treatment and follow-up
Regularly updated and reviewed by leading
oncology experts
>75 guidelines available from the ESMO website, OncologyPRO. Abridged versions available on the ESMO guidelines mobile
apps
> 20 patient friendly versions available on the
ESMO website, in different languages
ESMO MEETINGSIn 2018, nearly 36,000 oncology stakeholders met through ESMO’s events
EuropeESMO Congress
5 congresses3 symposia
4 educational courses14 preceptorships
AfricaESMO Summit Africa
ESMO Summit Middle East
AsiaESMO Asia Congress
7 preceptorships
ENSURING SUSTAINABLE CANCER CARELooking to the future for issues affecting all oncology professionals
Cancer Medicines Committee
Expensive, innovative cancer medicines
It aims to develop an economic model to tackle
issues related to reimbursement of
innovative medicines
Cancer Medicines Committee
Inexpensive, essential cancer medicines
Report on Cancer Medicines Shortages in Europe developed with
The Economist Intelligence Unit.
Recommendations made to policy makers on how to prevent and manage
shortages
ESMO-MCBS
Designed to assess the therapeutic benefit of
drugs registered for the treatment of cancer
Biosimilars
Tailored educational material for oncologists &
patientsESMO Colloquia on
biosimilars during ESMO 2018 & ESMO Asia 2018European Commission
2018 Stakeholder Event on Biosimilar Medicinal
Products
Magnitude of Clinical Benefit
Overall Survival,
Progression Free Survival
Toxicity
Costs
Prognosis of condition
Quality of lifeHR,
Long term survival,RR
Not analysed in view of significant “Heterogeneity”across Europe
ESMO-MCBS Factors taken into account
Metastatic NSCLC
aEMA approvals in 2016 to end August 2016. bESMO-MCBS version 1.0 [181], cEMA approval, October 2015dCo-primary end points (overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50% of tumour cells)
Therapy Disease setting
Trial Control Absolute survival gain HR(95% CI)
QoL/toxicity
MCBS scoreb
Nivolumab Advanced Nivolumab versus docetaxel in advanced squamous-cell NSCLC [98]
Phase III
NCT01642004
Docetaxel in patients with advanced SCC who have disease progression during or after 1st-line chemotherapy. Control OS 6 months
OS gain: 3.2 months. 2-year survival gain 15%
OS: HR for death 0.59 (0.44-0.79)
Improved toxicity profile
5(Form 2a)c
Nivolumab Advanced Nivolumab versus docetaxel in advanced non-squamous NSCLC [104] Phase IIINCT01673867
Docetaxel in patients with NSCC who progressed during or after platinum-based doublet chemotherapy. Control OS 9.4 months
OS gain: 2.8 months. 2-year survival gain 16%
OS: HR for death0.73 (0.59-0.89)
Improved toxicity profile
5(Form 2a)
Ramucirumab Advanced Ramucirumab plus docetaxel vs placebo + docetaxel for 2nd-line treatment of stage IV NSCLC after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial [94]Phase IIINCT01168973
Placebo + docetaxel in patients with SCC or NSCC who progressed during or after a 1st-line platinum-based chemotherapy regimen. Control OS 9.1 months
OS gain: 1.4 months OS: HR for death 0.86 (0.75-0.98)
Deteriorated toxicity profile
1(Form 2a)
Pembrolizumab Advanced Pembrolizumab vs docetaxel for previously treated, PD-L1-positive, advanced NSCLC (KEYNOTE-010): a randomised controlled trial [96]Phase IIINCT01905657
Docetaxel in patients with previously treated,PD-L1-positive, advanced NSCLC. Control OS 8.5 months
In PD-L1 >1%:dOS gain: 1.9 monthsIn PD- L1 >50%:d
OS gain: 6.7 months
In PD-L1 >1%:dOS: HR for death 0.71 (0.58–0.88)In PD-L1 >50%:d
OS: HR for death 0.54 (0.38–0.77)
Improved toxicity profile
In PD-L1 >1%: 3(Form 2a)In PD-L1 >50%: 5
(Form 2a)
ESMO-MCBS, SUBSTANTIAL IMPROVEMENTSESMO-MCBS – inclusion of scores in Guidelines
Distribution ESMO-MCBS grades FDA approved solid tumour drugs in 2015-2016
ESMO-MCBSSubstantial improvements
Limited clinical benefit of several anticancer agents approved by FDA in 2015–2016 according to ESMO-MCBS
Vivot et al, Ann Oncol 2017
No relation between price and clinical benefit of 38 FDA approved anticancer drugs 2000-2015
CHALLENGES & OPPORTUNITIES:MAJOR VALUE-BASED FRAMEWORKS -UPHOLDING PROVEN AS OPPOSED TO PROMISING
ESMO in action:Expensive Innovative Cancer Medicines
Outline of the model: Reimbursement based on local-referenced value
Value of “X” drug(tumor type/setting)
HE parametersMCBSFrequency of the disease
Adapt to the country/region level
Country/Region parameters:GDP% of GDP in health expendituresFrequency of the disease (registries, extrapolation)
Planned Outcome:•Models and Tools (template) •No specific discussions on specific drugs/regions Geographically-adapted value-based reimbursement
DELIVERING ON ESMO’S MISSION OF FACILITATING EQUAL ACCESS TO OPTIMAL CANCER CARE TO ALL CANCER PATIENTS
ESMO SUMMIT LATIN AMERICAMedical oncology education brought directly to you
We are here to listen to you!
ESMO SUMMIT LATIN AMERICA 2019 Sao Paulo, Brazil, 22-24 March 2019
Oncology Updates: From Evidence to Practice
Designed to address the specific challenges faced by oncology professionals practising in this
region
Local and international experts covering the cancer types most frequently encountered in Latin
America
Series of clinical case presentations followed by time for
discussion
To provide the oncology community with a summary of the most significant treatment advances presented at the ESMOcongresses
To review the current standard of care for key malignancies from a local and international perspective
To discuss the current controversies in the management of specific cancers
DELEGATESCountry breakdown Country Nr. of delegates
Brazil 293Mexico 9Chile 6Peru 3Uzbekistan 3Costa Rica 3El Salvador 2Ghana 2United States 2Argentina 1Australia 1Belgium 1Bolivia 1Canada 1Eritrea 1Japan 1Nigeria 1Philippines 1Syrian Arab Republic 1
333
87,99% Brazil
7,51% Rest of Latin America
0,30% Europe
4,20% Other
top related